Certara rises after up to $135 million sale of regulatory documents business

Certara

22/04/2026 14:45

** Shares of Certara CERT.O rise 2.4% to $6.35 in early trading

** The drug development software maker says it has reached an agreement to sell its regulatory and medical writing business to Veristat, a contract drug developer, for a consideration of up to $135 million

** The business provides services to make documents for drug development, ensuring compliance and timely submissions

** "This transaction underlines our commitment to the acceleration of AI-integrated modeling and simulation across the drug development lifecycle," CEO says

** In 2025, the business generated $50 million in revenue and $17 million in adjusted core profit

** CERT plans to update its 2026 forecast to reflect the sale upon the transaction's close

** Up to last close, stock had fallen 29.6% YTD

 (Reporting by Puyaan Singh)

 ((Puyaan.Singh@thomsonreuters.com;))